A phase II study of dasatinib in relapsed and-refractory chronic lymphocytic leukemia (CLL/SLL)

被引：6
|
作者：
Amrein, Philip C. [1 ]
Attar, Eyal C. [1 ]
Takvorian, Tak [1 ]
Hochberg, Ephraim P. [1 ]
Ballen, Karen [1 ]
Zabrieh, David [2 ]
Brown, Jennifer R. [2 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Dana Farber Canc Inst, Boston, MA USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.3126.3126
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3126
引用
收藏
页码：920A / 920A
页数：1
相关论文
共 50 条
  • [41] Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia
    Rogers, Kerry A.
    Thompson, Philip A.
    Allan, John N.
    Coleman, Morton
    Sharman, Jeff P.
    Cheson, Bruce D.
    Jones, Daniel
    Izumi, Raquel
    Frigault, Melanie M.
    Quah, Cheng
    Raman, Rakesh K.
    Patel, Priti
    Wang, Min Hui
    Kipps, Thomas J.
    HAEMATOLOGICA, 2021, 106 (09) : 2364 - 2373
  • [42] Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Hillmen, Peter
    Brown, Jennifer R.
    Byrd, John C.
    Eichhorst, Barbara F.
    Lamanna, Nicole
    O'Brien, Susan M.
    Qiu, Lugui
    Salmi, Tommi
    Hilger, James
    Huang, Jane
    Tam, Constantine S.
    BLOOD, 2019, 134
  • [43] Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Wierda, William G.
    Dorritie, Kathleen A.
    Munoz, Javier
    Stephens, Deborah M.
    Solomon, Scott R.
    Gillenwater, Heidi H.
    Gong, Lucy
    Yang, Lin
    Ogasawara, Ken
    Thorpe, Jerill
    Siddiqi, Tanya
    BLOOD, 2020, 136
  • [44] Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study
    Chanan-Khan, Asher
    Miller, Kena C.
    Musial, Laurie
    Lawrence, David
    Padmanabhan, Swaminathan
    Takeshita, Kenichi
    Porter, Carl W.
    Goodrich, David W.
    Bernstein, Zale P.
    Wallace, Paul
    Spaner, David
    Mohr, Alice
    Byrne, Catriona
    Hernandez-Ilizaliturri, Francisco
    Chrystal, Cynthia
    Starostik, Petr
    Czuczman, Myron S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) : 5343 - 5349
  • [45] Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
    Fischer, Kirsten
    Cramer, Paula
    Busch, Raymonde
    Stilgenbauer, Stephan
    Bahlo, Jasmin
    Schweighofer, Carmen D.
    Boettcher, Sebastian
    Staib, Peter
    Kiehl, Michael
    Eckart, Michael J.
    Kranz, Gabriele
    Goede, Valentin
    Elter, Thomas
    Buehler, Andreas
    Winkler, Dirk
    Kneba, Michael
    Doehner, Hartmut
    Eichhorst, Barbara F.
    Hallek, Michael
    Wendtner, Clemens-Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (26) : 3559 - 3566
  • [46] A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
    William, Basem M.
    Brillhart, Kaylee
    Afable, Manuel
    Bakalarz, Kristen
    Cooper, Brenda
    Lazarus, Hillard M.
    Gerson, Stanton L.
    Creger, Richard
    Nagabhushanam, Kalyanam
    Grote, James
    Fu, Pingfu
    Kunati, Sandeep
    Yang, Shuming
    Xu, Yan
    Woost, Philip
    Jacobberger, James
    de Lima, Marcos
    Caimi, Paolo
    BLOOD, 2018, 132
  • [47] Phase 1 Study of Lenalidomide and Ibrutinib in Combination with Rituximab in Relapsed and Refractory CLL and SLL
    Ujjani, Chaitra S.
    Wang, Hongkun
    Skarbnik, Alan P.
    Trivedi, Neel
    Ramzi, Pari
    Khan, Nadia
    Cheson, Bruce D.
    BLOOD, 2017, 130
  • [48] Phase I/II study of thrice weekly rituximab in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): A feasible and active regimen.
    Byrd, JC
    Grever, MR
    Davis, B
    Lucas, MS
    Park, K
    Goodrich, A
    Morrison, C
    Murphy, T
    Kunkel, L
    Grillo-Lopez, A
    Waselenko, JK
    Flinn, IW
    BLOOD, 1999, 94 (10) : 704A - 705A
  • [49] Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
    Siddiqi, Tanya
    Soumerai, Jacob D.
    Dorritie, Kathleen A.
    Stephens, Deborah M.
    Riedell, Peter A.
    Arnason, Jon
    Kipps, Thomas J.
    Gillenwater, Heidi H.
    Gong, Lucy
    Yang, Lin
    Ogasawara, Ken
    Thorpe, Jerill
    Wierda, William G.
    BLOOD, 2022, 139 (12) : 1794 - 1806
  • [50] Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG)
    Koeppler, Hubert
    Fuss, Harald
    Hurtz, Hans J.
    Knigge, Owe
    Losem, Christoph
    Reschke, Daniel
    Schmitz, Stephan
    Weide, Rudolf
    Weiss, Johann
    Hallek, Michael
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (02) : 238 - 241
12345